400 related articles for article (PubMed ID: 18053638)
1. Cytochrome P450s in the development of target-based anticancer drugs.
Purnapatre K; Khattar SK; Saini KS
Cancer Lett; 2008 Jan; 259(1):1-15. PubMed ID: 18053638
[TBL] [Abstract][Full Text] [Related]
2. Generalized proteochemometric model of multiple cytochrome p450 enzymes and their inhibitors.
Kontijevskis A; Komorowski J; Wikberg JE
J Chem Inf Model; 2008 Sep; 48(9):1840-50. PubMed ID: 18693719
[TBL] [Abstract][Full Text] [Related]
3. Cytochrome P450 pharmacogenetics and cancer.
Rodriguez-Antona C; Ingelman-Sundberg M
Oncogene; 2006 Mar; 25(11):1679-91. PubMed ID: 16550168
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms and significance of inhibitory drug interactions involving cytochrome P450 enzymes (review).
Murray M
Int J Mol Med; 1999 Mar; 3(3):227-38. PubMed ID: 10028046
[TBL] [Abstract][Full Text] [Related]
5. Polymorphism of human cytochrome P450 enzymes and its clinical impact.
Zhou SF; Liu JP; Chowbay B
Drug Metab Rev; 2009; 41(2):89-295. PubMed ID: 19514967
[TBL] [Abstract][Full Text] [Related]
6. Lenalidomide: in vitro evaluation of the metabolism and assessment of cytochrome P450 inhibition and induction.
Kumar G; Lau H; Laskin O
Cancer Chemother Pharmacol; 2009 May; 63(6):1171-5. PubMed ID: 19030860
[TBL] [Abstract][Full Text] [Related]
7. Cytochromes P450 and drug discovery.
Lamb DC; Waterman MR; Kelly SL; Guengerich FP
Curr Opin Biotechnol; 2007 Dec; 18(6):504-12. PubMed ID: 18006294
[TBL] [Abstract][Full Text] [Related]
8. Inhibition and induction of human cytochrome P450 enzymes: current status.
Pelkonen O; Turpeinen M; Hakkola J; Honkakoski P; Hukkanen J; Raunio H
Arch Toxicol; 2008 Oct; 82(10):667-715. PubMed ID: 18618097
[TBL] [Abstract][Full Text] [Related]
9. Computational approaches for predicting CYP-related metabolism properties in the screening of new drugs.
Crivori P; Poggesi I
Eur J Med Chem; 2006 Jul; 41(7):795-808. PubMed ID: 16644065
[TBL] [Abstract][Full Text] [Related]
10. Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agents.
Murray M
J Pharm Pharmacol; 2006 Jul; 58(7):871-85. PubMed ID: 16805946
[TBL] [Abstract][Full Text] [Related]
11. Interactions between human cytochrome P450 enzymes and steroids: physiological and pharmacological implications.
Zhang YY; Yang L
Expert Opin Drug Metab Toxicol; 2009 Jun; 5(6):621-9. PubMed ID: 19473111
[TBL] [Abstract][Full Text] [Related]
12. Drug interactions of H2-receptor antagonists involving cytochrome P450 (CYPs) enzymes: from the laboratory to the clinic.
Rendić S
Croat Med J; 1999 Sep; 40(3):357-67. PubMed ID: 10411963
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of fluorescence- and mass spectrometry-based CYP inhibition assays for use in drug discovery.
Bell L; Bickford S; Nguyen PH; Wang J; He T; Zhang B; Friche Y; Zimmerlin A; Urban L; Bojanic D
J Biomol Screen; 2008 Jun; 13(5):343-53. PubMed ID: 18474896
[TBL] [Abstract][Full Text] [Related]
14. The potential pharmacological and toxicological impact of P450 screening.
Riley RJ
Curr Opin Drug Discov Devel; 2001 Jan; 4(1):45-54. PubMed ID: 11727322
[TBL] [Abstract][Full Text] [Related]
15. Cytochrome P450-mediated metabolism in the human gut wall.
Thelen K; Dressman JB
J Pharm Pharmacol; 2009 May; 61(5):541-58. PubMed ID: 19405992
[TBL] [Abstract][Full Text] [Related]
16. Prediction of CYP-mediated drug interactions in vivo using in vitro data.
Foti RS; Wahlstrom JL
IDrugs; 2008 Dec; 11(12):900-5. PubMed ID: 19051152
[TBL] [Abstract][Full Text] [Related]
17. Mice as clinically relevant models for the study of cytochrome P450-dependent metabolism.
Muruganandan S; Sinal CJ
Clin Pharmacol Ther; 2008 Jun; 83(6):818-28. PubMed ID: 18388875
[TBL] [Abstract][Full Text] [Related]
18. Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway.
Lu H; Tonge PJ
Acc Chem Res; 2008 Jan; 41(1):11-20. PubMed ID: 18193820
[TBL] [Abstract][Full Text] [Related]
19. Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues.
Appiah-Opong R; de Esch I; Commandeur JN; Andarini M; Vermeulen NP
Eur J Med Chem; 2008 Aug; 43(8):1621-31. PubMed ID: 18249473
[TBL] [Abstract][Full Text] [Related]
20. [Role of cytochrome P450 enzymes in pharmaceutical preparations].
Baede van Dijk PA; de Graeff PA; Lekkerkerker JF
Ned Tijdschr Geneeskd; 1999 Dec; 143(52):2607-11. PubMed ID: 10633805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
